The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

This publication has 45 references indexed in Scilit:

• Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
  Cancer Research, 2005
• THE B7 FAMILY REVISITED
  Annual Review of Immunology, 2005
• Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
  Endocrine-Related Cancer, 2005
• Prognostic and Predictive Factors in Early-Stage Breast Cancer
  The Oncologist, 2004
• In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
  Blood, 2004
• Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis
  Journal of Neuroimmunology, 2004
• Vaccine and antibody-directed T cell tumour immunotherapy
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
  Cancer Research, 2004
• Cancer Statistics, 2004
  CA: A Cancer Journal for Clinicians, 2004
• Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation
  Bone Marrow Transplantation, 1997